Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

This is a double-blind, placebo-controlled, crossover trial in patients with resistant hypertension that were taking maximally tolerated doses of 3 or more drugs. The authors found that the average reduction in home systolic blood pressure by spironolactone was superior to placebo (-8•70 mm Hg [95% CI -9•72 to -7•69]; p<0•0001), superior to the mean of the other two active treatments (doxazosin and bisoprolol; -4•26 [-5•13 to -3•38]; p<0•0001), and superior when compared with the individual treatments; versus doxazosin (-4•03 [-5•04 to -3•02]; p<0•0001) and versus bisoprolol (-4•48 [-5•50 to -3•46]; p<0•0001). This supports the role of sodium retention in resistant hypertension. : Choosing peritoneal dialysis reduces the risk of invasive access interventions Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Nephrology Clinical Trial Results Hypertension Source Type: research